NCT01059864View on ClinicalTrials.gov

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Rheumatoid Arthritis
Interventions
DRUG

CP-690,550

12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12

DRUG

Atorvastatin

Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily

DRUG

CP-690,550

12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12

DRUG

Atorvastatin Placebo

Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily

Trial Locations (15)

29601

Pfizer Investigational Site, Greenville

32216

Pfizer Investigational Site, Jacksonville

35209

Pfizer Investigational Site, Birmingham

35801

Pfizer Investigational Site, Huntsville

44143

Pfizer Investigational Site, Mayfield Village

45417

Pfizer Investigational Site, Dayton

75013

Pfizer Investigational Site, Allen

85234

Pfizer Investigational Site, Gilbert

85251

Pfizer Investigational Site, Scottsdale

91786

Pfizer Investigational Site, Upland

110-744

Pfizer Investigational Site, Seoul

120-752

Pfizer Investigational Site, Seoul

133-792

Pfizer Investigational Site, Seoul

137-701

Pfizer Investigational Site, Seoul

143-729

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01059864 - Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 | Biotech Hunter | Biotech Hunter